Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis
- PMID: 31961625
- PMCID: PMC7822358
- DOI: 10.1590/S1677-5538.IBJU.2019.0360
Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis
Abstract
Background: The diagnostic value and suitability of prostate cancer antigen 3 (PCA3) for the detection of prostate cancer (PCa) have been inconsistent in previous studies. Thus, the aim of the present meta-analysis was performed to systematically evaluate the diagnostic value of PCA3 for PCa.
Materials and methods: A meta-analysis was performed to search relevant studies using online databases EMBASE, PubMed and Web of Science published until February 1st, 2019. Ultimately, 65 studies met the inclusion criteria for this meta-analysis with 8.139 cases and 14.116 controls. The sensitivity, specificity, positive likelihood ratios (LR+), negative likelihood ratios (LR-), and other measures of PCA3 were pooled and determined to evaluate the diagnostic rate of PCa by the random-effect model.
Results: With PCA3, the pooled overall diagnostic sensitivity, specificity, LR+, LR-, and 95% confidence intervals (CIs) for predicting significant PCa were 0.68 (0.64-0.72), 0.72 (0.68-0.75), 2.41 (2.16-2.69), 0.44 (0.40-0.49), respectively. Besides, the summary diagnostic odds ratio (DOR) and 95% CIs for PCA3 was 5.44 (4.53-6.53). In addition, the area under summary receiver operating characteristic (sROC) curves and 95% CIs was 0.76 (0.72-0.79). The major design deficiencies of included studies were differential verification bias, and a lack of clear inclusion and exclusion criteria.
Conclusions: The results of this meta-analysis suggested that PCA3 was a non-invasive method with the acceptable sensitivity and specificity in the diagnosis of PCa, to distinguish between patients and healthy individuals. To validate the potential applicability of PCA3 in the diagnosis of PCa, more rigorous studies were needed to confirm these conclusions.
Keywords: Meta-Analysis [Publication Type]; Prostate cancer, familial [Supplementary Concept]; prostate cancer antigen 3, human [Supplementary Concept].
Copyright® by the International Brazilian Journal of Urology.
Conflict of interest statement
None declared.
Figures





Comment in
-
Increase in submissions to International Brazilian Journal of Urology during Covid-19 quarentine.Int Braz J Urol. 2020 Sep-Oct;46(5):689-690. doi: 10.1590/S1677-5538.IBJU.2020.05.01. Int Braz J Urol. 2020. PMID: 32648411 Free PMC article. No abstract available.
Similar articles
-
Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.Arch Pathol Lab Med. 2018 Sep;142(9):1106-1112. doi: 10.5858/arpa.2017-0185-OA. Epub 2018 Mar 16. Arch Pathol Lab Med. 2018. PMID: 29547000
-
Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.Medicine (Baltimore). 2018 Oct;97(42):e12806. doi: 10.1097/MD.0000000000012806. Medicine (Baltimore). 2018. PMID: 30334974 Free PMC article.
-
Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis.Clin Genitourin Cancer. 2020 Oct;18(5):402-408.e5. doi: 10.1016/j.clgc.2020.03.005. Epub 2020 Mar 14. Clin Genitourin Cancer. 2020. PMID: 32280028
-
Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies.Minerva Urol Nefrol. 2019 Aug;71(4):373-380. doi: 10.23736/S0393-2249.18.03093-X. Epub 2018 Sep 10. Minerva Urol Nefrol. 2019. PMID: 30203935 Review.
-
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.Prostate. 2013 Feb 15;73(3):227-35. doi: 10.1002/pros.22561. Epub 2012 Jul 20. Prostate. 2013. PMID: 22821756
Cited by
-
Performance of PCA3 and TMPRSS2:ERG Within the Prostate Cancer Prevention Trial Risk Calculator Version 2 in a Lithuanian Cohort.Res Rep Urol. 2025 Mar 29;17:95-103. doi: 10.2147/RRU.S511523. eCollection 2025. Res Rep Urol. 2025. PMID: 40176971 Free PMC article.
-
Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels of S100A4 as a Detector in Plasma.Int J Mol Sci. 2022 Dec 29;24(1):547. doi: 10.3390/ijms24010547. Int J Mol Sci. 2022. PMID: 36613987 Free PMC article.
-
Impact of lifestyle in prostate cancer patients. What should we do?Int Braz J Urol. 2022 Mar-Apr;48(2):244-262. doi: 10.1590/S1677-5538.IBJU.2021.0297. Int Braz J Urol. 2022. PMID: 34472770 Free PMC article. Review.
-
miRNA Expression Patterns in Early- and Late-Stage Prostate Cancer Patients: High-Throughput Analysis.Biomedicines. 2023 Nov 16;11(11):3073. doi: 10.3390/biomedicines11113073. Biomedicines. 2023. PMID: 38002073 Free PMC article.
-
Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discov Oncol. 2025 May 30;16(1):954. doi: 10.1007/s12672-025-02763-1. Discov Oncol. 2025. PMID: 40445561 Free PMC article. Review.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
- 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. - PubMed
-
- Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15:9575–9578. - PubMed
- 4. Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15:9575-8. - PubMed
-
- Filella X, Foj L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Int J Mol Sci. 2016;17 - PMC - PubMed
- 5. Filella X, Foj L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Int J Mol Sci. 2016;17. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous